HighRAD Oncology AI Imaging Platform
AI platform tracking entire patient journey with multi-organ quantitative analysis
Software · Cloud SaaSCompany source
Company profile
About HighRAD
HighRAD is a medical imaging AI company that has developed an innovative FDA-cleared oncology imaging platform designed to revolutionize cancer care through advanced quantitative analysis. The company's platform tracks the entire oncology patient journey, offering profound insights into disease progression through longitudinal, multi-organ analysis. HighRAD's technology provides seamless connectivity with CT, MRI, and PET systems, delivering fully automated lesion detection, segmentation, and comparative measurements that significantly enhance radiologist productivity and treatment outcomes. The platform leverages proprietary Simultaneous Deep Learning technology (SimU-Net) and multi-channel anisotropic 3D U-Net classification for unparalleled lesion change detection. HighRAD's solution enables 3x faster assessment of oncology patient follow-ups, 75% speed improvement in measurement time, and 65% reduction in diagnostic reporting time. The platform supports personalized treatment planning through comprehensive quantitative data analysis compliant with RECIST 1.1 guidelines, serving healthcare facilities, pharmaceutical companies conducting clinical studies, and oncology care providers. Founded by leading experts from Hebrew University of Jerusalem and clinical radiology, HighRAD is headquartered in Tel Aviv, Israel, and is committed to improving clinical outcomes through advanced AI-powered imaging analysis.
Company description HighRAD official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at HighRAD?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- Multi-organ lesions
- Oncology
Who it serves
- Health Systems
- Oncologists
- Pharmaceutical companies
- Radiologists
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: CT systems, MRI systems, PACS, PET systems.
Geographic context
MarketsEurope · Israel · United States
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance obtained for oncology AI imaging platform
Partnerships
Recorded partners
- Dana-Farber Cancer Institute
- Hebrew University of Jerusalem
- Sheba Medical Center
- Stony Brook University
- University of Zagreb
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
iCAS-BR
Oncology imaging solution for breast analysis
Software · Cloud SaaSCompany source
iCAS-LG
Oncology imaging solution for lung analysis
Software · Cloud SaaSCompany source
iCAS-LV
Oncology imaging solution for liver analysis
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
iCAS-LVK231690 · 510k · Mar 1, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
3x faster assessment
Oncology patient follow-ups
75% speed-up
Measurements time of findings
65% reduction
Diagnostic reporting time
35% increase in reimbursement
Additional $15K per week
Undisclosed Healthcare Facility
Oncology patient follow-up assessment and diagnostic reporting efficiency
3x faster assessment of oncology patient follow-ups, 75% speed up in measurements time, 65% reduction in diagnostic reporting time, 35% increase in reimbursement by additional $15K/week
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Yossi Srour
CEO & President
Leo Joskowicz
Co-Founder & CTO
Jacob Sosna
Co-Founder, CMO & Chairman, SAB
Eyal Morag
Scientific Advisory Board
Thomas A. Abrams
Scientific Advisory Board
Pablo Riera Ros
Scientific Advisory Board
Boris Brkljacic
Scientific Advisory Board
Raanan Berger
Scientific Advisory Board
06 · Company updates
Updates from HighRAD
Recent articles published on HighRAD's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.